Loading clinical trials...

Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNCT06620913

Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/...

Lead sponsor: Hospices Civils de Lyon•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment232

Start dateMay 2024

Last updatedOct 1, 2024

Condition

CV2 Autoimmunity

Locations shown

Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est

Bron

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions